CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.227
-0.004 (-1.73%)
At close: Mar 9, 2026
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
290.91M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Silence Therapeutics | 559.00K |
| Northwest Biotherapeutics | 937.00K |
| Vaxart | 148.20M |
| BioStem Technologies | 292.21M |
| Nuo Therapeutics | 2.61M |
| Arch Biopartners | 115.29K |
| ZIVO Bioscience | 209.03K |
| Harvard Apparatus Regenerative Technology | 743.00K |
CytoDyn News
- 4 days ago - CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab - GlobeNewsWire
- 17 days ago - CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference - GlobeNewsWire
- 5 weeks ago - CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer - GlobeNewsWire
- 2 months ago - December 2025 Letter to Shareholders - GlobeNewsWire
- 3 months ago - CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 3 months ago - CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 4 months ago - CytoDyn Secures $30 Million Commitment from Yorkville Advisors - GlobeNewsWire
- 4 months ago - Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire